Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Intuit Inc. (INTU) vs Novartis AG (NVS) Price & Performance

Intuit Inc.Trade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Intuit Inc. vs Novartis AG — how do they compare? Intuit Inc. trades at $332.99 (market cap $92.03B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 3.2× Intuit Inc.'s market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.

INTUNVS
Market Cap
$92.03B$295.37B
Sector
TechnologyHealth
52-Week High
$717.21$168.62
52-Week Low
$255.07$119.31
Enterprise Value
$90.49B$336.69B
Dividend Yield
1.43%3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Intuit Inc.

Intuit (INTU) trades at $334.43, up 2.82% today, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. However, the stock faces headwinds from legal investigations into pricing disclosures and a recent 20% drop, as reported by Forbes on June 2, 2026.

The outlook is mixed: analyst consensus targets $402.26 (66.7% buy ratings), but legal risks and overbought RSI levels near 74.42 suggest caution. Revenue growth to $20.9B in 2026 and a high net margin of 21.9% support long-term value, yet near-term volatility may persist due to sentiment shifts.

Novartis AG

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Intuit Inc.

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.

Read more on INTU

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS